Dunning, Elise E.
Decourt, Boris
Zawia, Nasser H.
Shill, Holly A.
Sabbagh, Marwan N. http://orcid.org/0000-0001-8139-3309
Funding for this research was provided by:
National Institutes of Health (R01AG059008, R01AG073212, P30AG072980)
Barrow Neurological Foundation
Article History
Received: 24 August 2023
Accepted: 26 March 2024
First Online: 14 May 2024
Declarations
:
: Elise E. Dunning and Boris Decourt have nothing to disclose. Nasser H. Zawia discloses ownership of NeuroTau. Holly A. Shill has received research support from Intra-cellular Therapeutics, Transposon, Parkinson Study Group/UCB, Parkinson’s Foundation, NINDS, Supernus/US World Meds, MJFF, Jazz Pharmaceuticals, Barrow Neurological Foundation and Cerevel Therapeutics. She has served as a consultant for the Parkinson Study Group/Nq, Biogen, Abbvie, Sage/Biogen, Praxis, KeifeRx, and Fasikl and Jazz Pharmaceuticals. Marwan N. Sabbagh discloses ownership interest (stock or stock options) in NeuroTau, uMethod Health, Lighthouse Pharmaceuticals, and Athira; he consults for Alzheon, Biogen, Roche-Genentech, T3D, Eisai, Lilly, and KeifeRx.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.